These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1428725)

  • 81. Vinorelbine, ifosfamide, and cisplatin combination as salvage chemotherapy in advanced non-small cell lung cancer.
    Song SY; Kim WS; Kim K; Jung CW; Im YH; Kim HJ; Kang WK; Lee HG; Kwon OJ; Rhee CH; Park CH; Park K
    Jpn J Clin Oncol; 2003 Oct; 33(10):509-13. PubMed ID: 14623918
    [TBL] [Abstract][Full Text] [Related]  

  • 82. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
    Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D
    J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
    Hawkins DS; Felgenhauer J; Park J; Kreissman S; Thomson B; Douglas J; Rowley SD; Gooley T; Sanders JE; Pendergrass TW
    Cancer; 2002 Sep; 95(6):1354-65. PubMed ID: 12216105
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Risk-adapted chemotherapy of germ cell tumors with carboplatin, etoposide and bleomycin for low-risk and cisplatin, etoposide and ifosfamide for high-risk patients. A single-center study.
    Tscherry G; Jacky E; Jost LM; Stahel RA
    Oncology; 2000 Aug; 59(2):110-7. PubMed ID: 10971168
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Ifosfamide/mesna and hematuria.
    Pratt CB; Goren MP
    Cancer Treat Rep; 1987 Nov; 71(11):1124-5. PubMed ID: 3119210
    [No Abstract]   [Full Text] [Related]  

  • 86. Etoposide, ifosfamide, and cisplatin therapy for refractory childhood solid tumors. Response and toxicity.
    van Hoff J; Grier HE; Douglass EC; Green DM
    Cancer; 1995 Jun; 75(12):2966-70. PubMed ID: 7773949
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Ifosfamide and mesna for the treatment of advanced squamous cell head and neck cancer. A GETLAC study.
    Cervellino JC; Araujo CE; Pirisi C; Francia A; Cerruti R
    Oncology; 1991; 48(2):89-92. PubMed ID: 1900124
    [TBL] [Abstract][Full Text] [Related]  

  • 88. [DNCE regimen for treatment of refractory or relapsed aggressive and highly aggressive non-Hodgkin lymphoma].
    Liu XM; Wang HQ; Zhang HL; Qiu LH; Li W; Li LF; Cui XZ; Liu PF; Hao XS
    Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):779-82. PubMed ID: 19173813
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.
    Rodriguez MA; Cabanillas FC; Velasquez W; Hagemeister FB; McLaughlin P; Swan F; Romaguera JE
    J Clin Oncol; 1995 Jul; 13(7):1734-41. PubMed ID: 7602363
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector.
    Falkson CI; Falkson HC; Falkson G
    Invest New Drugs; 1989 Jul; 7(2-3):261-7. PubMed ID: 2507474
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Clinical overview of mesna.
    Burkert H
    Cancer Treat Rev; 1983 Sep; 10 Suppl A():175-81. PubMed ID: 6414692
    [TBL] [Abstract][Full Text] [Related]  

  • 92. An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma.
    Falkson G; Hunt M; Borden EC; Hayes JA; Falkson CI; Smith TJ
    Invest New Drugs; 1992 Nov; 10(4):337-43. PubMed ID: 1487409
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Feasibility and efficacy of arginine 2-mercaptoethanesulfonate (ARGIMESNA) in the prevention of hemorragic cystitis from ifosfamide (IFO).
    Frustaci S; Foladore S; De Pascale A; Freschi A; Lo Re G; Sorio R; Errante D; Monfardini S
    Ann Oncol; 1992 Apr; 3 Suppl 2():S115-8. PubMed ID: 1622852
    [TBL] [Abstract][Full Text] [Related]  

  • 94. High-dose continuous-infusion ifosfamide in advanced thymic epithelial Tumors: A TYME network study.
    Conforti F; Pala L; Vivanet G; Corti C; Catania C; Maiettini D; Varano G; Di Venosa B; Curigliano G; Salvini P; Berardi R; Ballatore Z; De Pas TM
    Lung Cancer; 2023 Feb; 176():98-102. PubMed ID: 36630822
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Ifosfamide-induced acute kidney injury in a patient with leiomyosarcoma: A case report.
    Boskabadi J; Yousefi-Mazhin E; Salehifar E
    Cancer Rep (Hoboken); 2022 Oct; 5(10):e1666. PubMed ID: 35830327
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Feasibility and safety of outpatient administration of ifosfamide and etoposide for pediatric patients with Ewing sarcoma in a resource-limited setting amid the COVID-19 pandemic.
    Sarfraz S; Saeed H
    Pediatr Blood Cancer; 2022 May; 69(5):e29595. PubMed ID: 35234343
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Cutaneous reaction to ifosfamide plus mesna treated with desensitization challenge: a case report.
    Delgado-Prada A; Borrás J; Farzanegan R; Torres Gorriz MC; Germán-Sánchez A; Cervera Aznar R; Raducan I; Castelló JV; Sanchez-Hernandez A; Enrique E
    Clin Mol Allergy; 2022 May; 20(1):7. PubMed ID: 35606850
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Transitioning ifosfamide chemotherapy regimens to the ambulatory setting: reviewing cost savings and safety profile.
    Banh C; Valsvik K; Arredondo A; Notbohm K; Elquza E; Babiker H; Kraft A; Boiles AR; Persky D; Ortega A; McBride A
    Support Care Cancer; 2022 Mar; 30(3):2755-2766. PubMed ID: 34825982
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Ifosfamide cardiotoxicity in humans.
    Kandylis K; Vassilomanolakis M; Tsoussis S; Efremidis AP
    Cancer Chemother Pharmacol; 1989; 24(6):395-6. PubMed ID: 2791194
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Ifosfamide-Induced Malignancy of Ureter and Bladder.
    Sannu A; Radha R; Mathews A; Padmakumari Mony R; Prahladan A; James FV
    Cureus; 2017 Aug; 9(8):e1594. PubMed ID: 29062626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.